The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility.
Recommended Citation
Holland BC, Shetty Z, and Alanee S. The effect of targeted therapy for genitourinary malignancies on sexual function and fertility. Curr Urol Rep 2017; 18(8):65.
Document Type
Article
Publication Date
8-1-2017
Publication Title
Current urology reports
Abstract
PURPOSE OF REVIEW: Targeted therapy for genitourinary cancer is being used at an increasing rate. These medications show great survival benefit but are relatively lacking in long-term adverse effect data. With increasing survivability, measures to improve quality of life must be considered for GU cancer and a large proponent of this is sexual function.
RECENT FINDINGS: mTOR inhibitors have shown an effect on testosterone levels and may have a link to abnormal semen parameters. Tyrosine kinase inhibitors (TKIs) have shown no adverse sexual outcomes in the literature. There are laboratory links to tyrosine kinases having a beneficial effect on erectile and sexual function. Possible sexual side effects must be discussed with patients receiving a diagnosis of cancer. Further research is required to determine the exact mechanisms and outcomes of sexual function with new and emerging targeted therapy.
Medical Subject Headings
Animals; Fertility; Humans; Male; Molecular Targeted Therapy; Penile Erection; Protein Kinase Inhibitors; Quality of Life; Sexual Dysfunction, Physiological; Sexuality; TOR Serine-Threonine Kinases; Urogenital Neoplasms
PubMed ID
28712040
Volume
18
Issue
8
First Page
65
Last Page
65
